VOLITIONRX LTD — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VOLITIONRX LTD filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.73M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.23M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $775.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $306.4K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $90.0K | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $13.4K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $17.1K | Mar 22, 2021 |
| FY2014 | Dec 31, 2014 | $14.8K | Mar 18, 2015 |
| FY2013 | Dec 31, 2013 | $55.0K | Mar 28, 2014 |
| FY2013 | Dec 31, 2012 | $55.0K | Mar 28, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.36M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($26.97M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($35.68M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($30.60M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($26.99M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($20.40M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($16.10M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($18.01M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($14.77M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($11.91M) | Mar 1, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.74M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($27.02M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($35.99M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($31.78M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($28.33M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($21.25M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($16.04M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($17.90M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($14.70M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($12.43M) | Mar 1, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.08M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $14.41M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $19.55M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $15.33M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $13.02M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $14.53M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $10.36M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $10.91M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $8.03M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $7.90M | Mar 1, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.68M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($25.89M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($18.06M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($15.28M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($20.85M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($16.46M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($12.74M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($14.73M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($12.19M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($8.86M) | Mar 1, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.6K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $277.5K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.08M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.57M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $973.6K | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.94M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $511.3K | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($301.8K) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.43M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $415.1K | Mar 1, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.90M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.40M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $27.95M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.30M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $27.49M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $26.15M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $21.29M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $17.49M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $14.62M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $24.73M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $35.51M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $36.66M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.42M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $9.77M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $9.86M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $7.09M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $5.35M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $4.67M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $3.56M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.25M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($24.91M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.80M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.57M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $17.72M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $16.29M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $14.20M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $12.14M | Mar 22, 2021 |
| FY2019 | Dec 31, 2017 | $9.96M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $21.18M | Mar 13, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($252.90M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($229.54M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($202.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($167.26M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($136.99M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($110.17M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($89.82M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($73.72M) | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | ($55.71M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($40.94M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.26M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $20.73M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.87M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $20.58M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $19.44M | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $16.97M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $13.43M | Mar 22, 2021 |
| FY2018 | Dec 31, 2017 | $10.12M | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | $21.68M | Mar 13, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.71M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $4.81M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $4.83M | Mar 25, 2024 |
| FY2022 | Dec 31, 2022 | $3.85M | Mar 15, 2023 |
| FY2021 | Dec 31, 2021 | $3.07M | Mar 30, 2022 |
| FY2020 | Dec 31, 2020 | $3.45M | Mar 22, 2021 |
| FY2019 | Dec 31, 2019 | $2.84M | Feb 20, 2020 |
| FY2018 | Dec 31, 2018 | $2.40M | Mar 13, 2019 |
| FY2017 | Dec 31, 2017 | ($157.5K) | Mar 1, 2018 |
| FY2016 | Dec 31, 2016 | $162.4K | Mar 10, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 125.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 96.10M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 81.90M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 57.87M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 53.77M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 48.61M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 41.13M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | 35.34M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | 26.52M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 26.13M | Mar 1, 2018 |